Theratechnologies

Theratechnologies Inc., a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that increases the target protein's resistance to enzymatic degradation. Its lead product is tesamorelin, which completed its phase III clinical trial for the treatment of HIV-associated lipodystrophy and is in phase II clinical trials for the treatment of mild cognitive impairment and growth hormone deficient abdominal obesity. The company also develops Acute kidney injury, a preclinical stage product. It has a license agreement with PDC Biotech GmbH to use the antagonists of the prostaglandin F2a receptor in pre-term labor and primary dysmenorrheal; and OctoPlus N.V. to develop and commercialize GLP-1 portfolio of analogues. The company also has a collaboration and licensing agreement with EMD Serono, Inc. for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded in 1993 and is headquartered in Montreal, Canada.

Theratechnologies headquartered in North America, operates in the Biotechnology, Pharmaceutical, Therapeutics sector. The company focuses on Biotechnology and has secured $14.4B in funding across 72 round(s). With a team of 51-100 employees, Theratechnologies is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Theratechnologies, raised $11.0M. Discover more about their projects, partnerships, and impact on our platform.